SLS News and Press, SELLAS Life Sciences Group Inc. From 10/31/23

2023-10-31 08:53:38 ET More on SELLAS Life Sciences Sellas Life Sciences stock jumps on FDA fast track designation for PTCL treatment SELLAS gains on FDA orphan drug status for its SLS009 Seeking Alpha’s Quant Rating on SELLAS Life Sciences Historical ...

2023-10-31 08:31:19 ET Losers: Sarepta Therapeutics ( SRPT ) -43% announces topline results from EMBARK, a global pivotal study of ELEVIDYS gene therapy for Duchenne muscular dystrophy. Petmed Express PETS -26% after Q2 earning release . SELLAS Life Science...

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...

2023-10-30 09:16:26 ET Sellas Life Sciences ( NASDAQ: SLS ) shares jumped 22% premarket on Monday after the biopharmaceutical company gained FDA's fast track designation for SLS009 for treatment of relapsed/refractory peripheral T-cell lymphomas (PTCL). SLS009 is a highl...

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% - - Fast Track Designation Accelerates SLS009's Path to U.S. FDA Submission for Treatment of r/r ...

NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...

– SLS009 Is First CDK9 Inhibitor in Combination with AZA/VEN to Achieve Complete Response in AML Patient Resistant to Venetoclax Combination Therapies – – First Patient Enrolled Achieved CR and in Fifth Month of Treatment; Four Patients Continue on Treatment...

2023-10-13 10:00:01 ET More on Health Care Select Sector SPDR Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further...

- Enrollment ex-China Expected to be Completed in November 2023 – - Enrollment in China Expected to Commence this Quarter - NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), ...

2023-10-12 08:22:14 ET More on Beyond Meat, SELLAS Life Sciences, etc. Beyond Meat Continues To Look Potentially Beyond Repair Beyond Meat: The Core Question Here Is Liquidity Beyond Meat: Pain Is Far From Over SELLAS gains on FDA orphan drug status for its S...